September 14, 2020
Stemson Therapeutics announced approval in the United States of US patent No. 10716808, entitled “Methods and compositions to modulate hair growth” licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. The patent covers a novel process developed by Stemson co-founder and Chief Scientific Officer, Alexey Terskikh, PhD, to differentiate Induced Pluripotent Stem Cells (iPSC) into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. Issuance of this foundational patent provides stability surrounding the company’s efforts to develop its breakthrough iPSC-based solution for hair growth.
Read More »
September 8, 2020
Stemson Therapeutics is pleased to announce Meghan Samberg, PhD, joined our team as Vice President, R&D and Preclinical Development. Dr. Samberg will lead Stemson’s research and development efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.
“Meghan brings extensive preclinical and clinical research experience and adds depth to the Stemson management team. Her expertise in tissue engineering strategies,
Read More »
September 11, 2019
Stemson Therapeutics is pleased to announce Cenk Sumen, PhD, will join our team as Chief Technology Officer. Dr. Sumen will lead Stemson’s manufacturing efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy. He will join Stemson’s executive team, reporting to Geoff Hamilton, Chief Executive Officer of Stemson, and will serve on the company Board of Directors.
“Cenk brings almost a decade of experience translating early stage cell therapy candidates into GMP compliant manufacturing environments.
Read More »
June 27, 2019
Today, Stemson Therapeutics announced a significant investment in its seed financing round by Allergan, a leading global pharmaceutical company. The investment will advance Stemson’s final product development in preparation for human clinical trials, and provide Allergan with a promising new product pipeline for its market leading Medical Aesthetics portfolio. The investment with Stemson represents Allergan’s first step into iPSC-based cell therapy technology. iPSC’s have the potential to become any cell type in the human body and hold great promise to deliver breakthrough regenerative medicine therapies in the future.
Read More »
June 26, 2019
Sanford Burnham Prebys scientist and Stemson Therapeutics Co-Founder demonstrates functional hair follicles grown from stem cells at International Society for Stem Cell Research (ISSCR) annual meeting.
Download the press release
Read More »
May 31, 2019
Sanford Burnham Prebys Medical Discovery Institute researchers Dr. Alexey Terskikh and Dr. Antonella Pinto have won a prize for best poster at the 2019 UC San Diego Division of Regenerative Medicine Symposium and a merit award for best abstract at the 2019 International Society for Stem Cell Research Annual Meeting. The poster and abstract highlighted the use of Dermal Papilla cells derived from human Induced Pluripotent Stem Cells (iPSC) to grow partially humanize de novo hair follicles in nude mice.
Read More »
May 24, 2019
David H Sachs, MD, a renowned transplant immunologist at Columbia University Medical Center and Massachusetts General Hospital, will serve as a key consultant in guiding the testing and development of Stemson Therapeutics’ hair growth cell therapy. Dr. Sachs brings over 45 years of experience in testing transplantation tolerance of allografts and xenografts. He is the author of over 700 articles in scientific journals and has pioneered the development of animal models to test transplantation tolerance.
Read More »
April 15, 2019
Stemson Therapeutics has established its headquarters in La Jolla, CA on the Sanford Burnham Prebys Medical Discovery Institute (SBP) campus, centered in one of the premier biomedical research hubs in the United States. Stemson’s unique cell therapy solution to treat alopecia is based on Induced Pluripotent Stem Cell (iPSC) technology originally developed at SBP by Stemson co-founder, Dr. Alexey Terskikh. By incubating within the institute, Stemson will have access to world class research and development facilities to support the final product development in preparation for clinical trials.
Read More »
March 14, 2019
Matt Posard, former senior executive at Illumina, has joined the Stemson Therapeutics team as Executive Chairman of the Board. Matt brings over 30 years of executive experience in the life sciences industry. He helped grow three companies – BioSite, GenProbe and Illumina – from early stage commercialization to major global success. He is a seasoned board member and currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Dermtech, Talis BioMedical, Ingite Bio, and Fabric Genomics.
Read More »
January 1, 2019
Stemson Therapeutics welcomes Dr. Hideyuki Okano and Dr. Michael Rendl as scientific advisors, as well as Dr. Richard Chaffoo and Dr. Paul McAndrews as medical advisors. Okano is a stem cell biologist with deep experience in Induced Pluripotent Stem Cells (iPSC) and their translation into therapeutic use. Dr. Rendl is a stem cell biologist focusing on hair follicle formation. Together, Drs. Okano and Rendl will guide the scientific and biological development of the Stemson Therapeutics hair growth cell therapy.
Read More »
